NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
10/01/2024
Back to search
Official data from USPTO
XDC THE BIOCONJUGATION LEADER
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
21
Latest update
10/01/2024
Trademark type
Combined
Nice classes
40, 42
Filing date
07/03/2023
Registration date
10/01/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/01/2024
Last transaction
10/01/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
10/20/2023
First use in commerce
10/20/2023
Drawing code
3
Owner type
03
Owner location
Grand Cayman, KY
Examiner
SCHMIDT, JOHN
Law office
N10
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized wording "XDC" to the right of an incomplete oval outline that intersects with another incomplete oval outline. The stylized wording "The Bioconjugation Leader" appears below "XDC".
Holders and representatives
Holders
WuXi XDC Cayman Inc.
Representatives
Eric Lamb FROST BROWN TODD LLP
Technical classification
Nice Classes
Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 40
Custom assembling of materials for others; custom manufacturing of pharmaceuticals; custom manufacturing of drug conjugates; custom production of pharmaceuticals; custom production of biological preparations; custom manufacturing of antibody-drug conjugates; custom manufacturing of chemical reagents; custom manufacturing of pharmaceutical preparations; custom manufacturing of biomedical preparations; custom manufacture of drug conjugates; processing of pharmaceutical preparations; processing or treating of chemical reagents; processing of antibody drugs; custom manufacturing of antibody drugs; processing of biomedical preparations; processing of biotechnology drug
Class 42
Development of products for others in the field of pharmaceuticals; pharmaceutical drug development services; research and development of new products in the field of pharmaceuticals; biochemical research and development; custom design and development of chemical reagent antibodies and conjugate antibodies; research and development in the pharmaceuticalbiomedicine and biotechnology fields; research and development of antibodies; research and development of conjugated antibodies; biomedical research services; development of pharmaceutical preparations and medicines; research and development of antibody-drug conjugates; research and development of drug conjugates; preclinical research and evaluation of new drugs; consulting services in the field of technology development; research and development of new products for others; scientific research and development
Publications
History of USPTO decisions and trademark events.
21 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
10/01/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
08/28/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
08/28/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
07/07/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
07/06/2024
IUAF
USE AMENDMENT FILED
05/29/2024
EISU
TEAS STATEMENT OF USE RECEIVED
05/29/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
02/06/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/12/2023
PUBO
PUBLISHED FOR OPPOSITION
12/12/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/22/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/03/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
11/03/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/03/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
11/03/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/03/2023
DOCK
ASSIGNED TO EXAMINER
10/31/2023
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
08/04/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/03/2023
NWAP
NEW APPLICATION ENTERED
07/06/2023
Continuous trademark protection
Get notified about every new filing that threatens XDC THE BIOCONJUGATION LEADER or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.